Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Disease Progression × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 244 Glioma 99 Brain Neoplasms 94 Gliosarcoma 80 Astrocytoma 58 Central Nervous System Neoplasms 57 Oligodendroglioma 41 Melanoma 40 Neuroblastoma 24 Recurrence 19 Ependymoma 16 Neoplasm Metastasis 15 Medulloblastoma 15 Neoplasms 14 Sarcoma, Ewing 12 Lymphoma 11 Sarcoma 10 Rhabdomyosarcoma 10 Diffuse Intrinsic Pontine Glioma 10 Neuroendocrine Tumors 9 Lung Neoplasms 8 Unspecified Adult Solid Tumor, Protocol Specific 6 Small Cell Lung Carcinoma 6 Colorectal Neoplasms 6 Osteosarcoma 5 Optic Nerve Glioma 5 Neuroectodermal Tumors, Primitive 5 Choroid Plexus Neoplasms 5 Breast Neoplasms 5 Wilms Tumor 4

Interventions

pembrolizumab 2 fludarabine 2 Radiosurgery 2 Paclitaxel 2 Cyclophosphamide 2 Cisplatin 2 Carboplatin 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 pazopanib 1 niraparib 1 lutetium Lu 177 dotatate 1 ibrutinib 1 grapiprant 1 fludarabine phosphate 1 famitinib 1 encorafenib 1 copanlisib 1 cemiplimab 1 capivasertib 1 camrelizumab 1 brigatinib 1 binimetinib 1 axicabtagene ciloleucel 1 avasopasem manganese 1 abexinostat 1 Transplantation, Autologous 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02761070 2023-03-08

RE-GEND

Kyorin University

Phase 3 Unknown

Glioblastoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡